Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02207686|
Recruitment Status : Unknown
Verified November 2015 by Marie Luise Bisgaard, MD, University of Copenhagen.
Recruitment status was: Enrolling by invitation
First Posted : August 4, 2014
Last Update Posted : November 13, 2015
The investigators aim to analyze tumors from vHL patients who have different courses of disease and different types of VHL gene alterations to characterize which types of genetic alterations the tumors contain and how these alterations affect the tumor cells' behavior on a molecular level. The investigators will then compare these observations to vHL disease outcome in patients and families.
It is already known that most vHL tumors develop when both copies of the VHL gene in a cell are inactivated. The first copy is inactivated in all the person's cells from birth ("first hit"), leaving just one functional copy. A tumor can develop from cells where the second copy is also inactivated ("second hit"). So far, only the molecular consequences of the first hit have been investigated. It is our hypothesis that both the first and second hits in combination have consequences for tumor development and clinical outcome. The investigators will include tumors from patients with different disease courses and different types of "first hits" and analyse the tumors' DNA in order to find correlations between the first and second hits and patients' and families' medical histories. The investigators hereby hope to give new insights into how vHL tumors grow and which genetic factors influence tumor development. These results will contribute to the current knowledge of vHL and help us get one step closer to be able to predict an individual's tumor risks and need for surveillance.
|Condition or disease|
|Von Hippel-Lindaus Disease|
In vHL tumors from patients with different phenotypes and different genetic backgrounds, the investigators aim to assess both the nature of germline and somatic VHL mutations along with the total residual VHL protein (pVHL) activity in tumor cells and evaluate association to disease outcome in patients and families.
vHL tumor development follows Knudson's "two-hit-mode": patients are born with a germline mutation in one copy of their VHL gene in all the cells of the body - "the first hit". Somatic mutation in the other copy of the VHL gene - "the second hit" - initiates tumor development. Pheno-genotype correlations are well known in vHL, but have so far been explained exclusively by the nature of the germline mutation (the first hit). It is the investigators' hypothesis that it is the total residual activity of the protein (pVHL) present in the tumor after both first and second hit, which decides each tumor's destiny.
The investigators will apply Sanger sequencing, MLPA (and multiplex ligation dependent probe amplification), LOH (Loss of heterogeneity) analysis, methylation assays, FISH (Fluorescence In Situ Hybridization), and immunohistochemistry to characterize the germline and somatic mutations, determine presence of mRNA and pVHL, and assess residual VHL activity in each tumor. All these methods are already established in our laboratory.
The results will give deeper insight to vHL tumorigenesis and pave the road to future individual prediction of each patient´s course of disease and need for surveillance.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?|
|Study Start Date :||September 2014|
|Estimated Primary Completion Date :||August 2016|
|Estimated Study Completion Date :||August 2017|
von Hippel-Lindau disease
Patients with von Hippel-Lindau disease who have had at least one vHL-related tumor removed
- Residual pVHL activity measured by amount of VHL mRNA in tumor cells [ Time Frame: Two years ]We will correlate amount of VHL mRNA in tumor cells with the type of the patients' first hit (germline mutation) and the tumor's second hits (somatic mutations).
- Presence of VHL protein (pVHL) in tumor cells [ Time Frame: Two years ]We will correlated the presence of pVHL in tumor cells with the nature of the patients' (germline mutation) and the tumor cells' second hits (somatic mutations).
- Type of second hit (somatic mutation) found in DNA from tumor cells [ Time Frame: One year ]We will correlate the type of germline mutation found in the patient's DNA from blood with the types of second hits (somatic mutations) found in the tumor's DNA.
- Patient's age at tumor diagnosis [ Time Frame: Two years ]For each tumor we will correlate the previous outcome measures to the patient's age at tumor diagnosis
- Patient's total tumor burden [ Time Frame: Two years ]For each tumor we will correlate the previous outcome measures to the patient's total tumor burden
- Type of clinical vHL in the patient's family (e.g. type 1, type 2) [ Time Frame: Two years ]For each tumor we will correlate the previous outcome measures to the type of clinical vHL found in the patient's family.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02207686
|Department of Cellular and Molecular Medicine, University of Copenhagen|
|Copenhagen, Copenhagen N, Denmark, DK-2200|
|Principal Investigator:||Marie Luise Bisgaard, MD||Department of Cellular and Molecular Medicine, University of Copenhagen|